| Drug General Information |
| Drug ID |
D0G9AW
|
| Former ID |
DNCL003442
|
| Drug Name |
GS-9973
|
| Drug Type |
Small molecular drug
|
| Indication |
B-cell lymphoma [ICD9: 202.8; ICD10:C85.1]
|
Phase 2 |
[1],
[2]
|
|---|
| Company |
Gilead Sciences
|
| Structure |
|
Download
2D MOL
|
| Formula |
C23H21N7O
|
| InChI |
InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)
|
| InChIKey |
XSMSNFMDVXXHGJ-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
141083150, 172130706, 175427696, 182111926, 184525791, 184525809, 184525827, 184525846, 196411449, 198989653, 210275460, 210281108, 226088099, 228590974, 242058626, 242638282, 242852135, 247777133, 249565580, 252451739, 252471851
|
| Target and Pathway |
| Target(s) |
Tyrosine-protein kinase SYK |
Target Info |
Modulator |
[3]
|
|---|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Osteoclast differentiation
|
|
Platelet activation
|
|
Natural killer cell mediated cytotoxicity
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
Tuberculosis
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesis
|
|
PANTHER Pathway
|
B cell activation
|
|
Pathway Interaction Database
|
Fc-epsilon receptor I signaling in mast cells
|
|
BCR signaling pathway
|
|
GMCSF-mediated signaling events
|
|
Atypical NF-kappaB pathway
|
|
Osteopontin-mediated events
|
|
FAS (CD95) signaling pathway
|
|
Thromboxane A2 receptor signaling
|
|
IL2-mediated signaling events
|
|
Class I PI3K signaling events
|
|
Alpha-synuclein signaling
|
|
PathWhiz Pathway
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Reactome
|
GPVI-mediated activation cascade
|
|
FCGR activation
|
|
Regulation of actin dynamics for phagocytic cup formation
|
|
Role of phospholipids in phagocytosis
|
|
DAP12 signaling
|
|
Fc epsilon receptor (FCERI) signaling
|
|
Role of LAT2/NTAL/LAB on calcium mobilization
|
|
FCERI mediated MAPK activation
|
|
FCERI mediated Ca+2 mobilization
|
|
Integrin alphaIIb beta3 signaling
|
|
Interleukin-2 signaling
|
|
CLEC7A (Dectin-1) signaling
|
|
Dectin-2 family
|
|
Regulation of signaling by CBL
|
|
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
WikiPathways
|
IL-2 Signaling Pathway
|
|
IL-3 Signaling Pathway
|
|
Fc epsilon receptor (FCERI) signaling
|
|
Signaling by the B Cell Receptor (BCR)
|
|
Interleukin-2 signaling
|
|
Fcgamma receptor (FCGR) dependent phagocytosis
|
|
DAP12 interactions
|
|
B Cell Receptor Signaling Pathway
|
|
RANKL/RANK Signaling Pathway
|
|
Integrin alphaIIb beta3 signaling
|
|
GPVI-mediated activation cascade
|
|
Regulation of toll-like receptor signaling pathway
|
|
IL-5 Signaling Pathway
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7889). |
|---|
| REF 2 | Clinical pipeline report, company report or official report of Gilead. |
|---|
| REF 3 | An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. |
|---|
